CT38

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Jump to: navigation, search


CT38 is an experimental peptide (i.e., two or more amino acids linked in a chain) that acts as an agonist for CRF2 (corticotropin-releasing factor 2).[1] CT38 is a drug developed by Cortene.[2]

Theory[edit | edit source]

Evidence[edit | edit source]

Clinicians[edit | edit source]

Lucinda Bateman is the principal investigator for a current clinical trial of CT38 for ME/CFS, it is only being tested on patients who meet both the Canadian Consensus Criteria for myalgic encephalomyelitis and the Fukuda criteria for chronic fatigue syndrome.[1]

Risks and safety[edit | edit source]

Costs and availability[edit | edit source]

Notable studies[edit | edit source]

Articles, talks and interviews[edit | edit source]

Learn more[edit | edit source]

See also[edit | edit source]

References[edit | edit source]


The information provided at this site is not intended to diagnose or treat any illness.

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history